The U.S. Food & Drug Administration (FDA) will host a series of webinars to provide more in-depth information about the details outlined in the Infant Formula Transition Plan for Exercise of Enforcement Discretion and address questions.
The guidance outlines a pathway for manufacturers of infant formula under enforcement discretion to market infant formula products that may not currently comply with specific FDA requirements while they work toward meeting those requirements. Under the new guidance, the period of enforcement discretion for those products identified in the letters of enforcement discretion will be extended until Jan. 6, 2023, with further extensions possible for firms that express interest in and take steps toward the lawful marketing of such products in the United States.  The guidance balances the need to ensure that infant formula products meet regulatory requirements with the need for a more resilient infant formula supply.  
Each webinar will have a specific focus and starts at 2:00pm ET.
October 21, 2022: Infant Formula Enforcement Discretion Transition Guidance Overview

November 4, 2022: New Infant Formula Submission Requirements

November 10, 2022: Quality Factor Requirement – Sufficient Biological Quality of Protein

November 17, 2022: Quality Factor Requirement – Normal Physical Growth

One registration provides access to all four webinars.

Question Title

* 1. Contact Information

Question Title

* 2. What sector best represents you or your organization?

Question Title

* 3. If you would like to submit a question or brief comment related to the Infant Formula Transition Plan for Exercise of Enforcement Discretion, please enter in the field below.